Innocoll Priced, Nasdaq: INNL
Develops absorbable collagen drugs to treat pain, foot infections and adhesions.
Industry: Health Care
First Day Return: 0.0%
INNL
Develops absorbable collagen drugs to treat pain, foot infections and adhesions.
| IPO Data | |
|---|---|
| IPO Date | 07/24/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $59 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Athlone, Ireland |
| Founded | 1997 |
| Employees at IPO | 90 |
| Website www.innocollinc.com | |
IPO News for Innocoll
Innocoll (INNL) Performance
